Format

Send to

Choose Destination
Drugs Context. 2018 Dec 27;7:212558. doi: 10.7573/dic.212558. eCollection 2018.

Anti-angiogenesis therapy, synthetic lethality, and checkpoint inhibition in ovarian cancer: state of the science and novel combinations.

Author information

1
University of California Irvine Medical Center, Orange, CA 92868, USA.

Abstract

Over the last decade, new therapeutics in the form of anti-angiogenic treatment, synthetic lethality, and checkpoint inhibition have offered new options for the treatment of ovarian cancer. This review summarizes studies related to these treatment modalities and additionally novel combinations that offer a veritable therapeutic matrix for clinicians to choose from.

KEYWORDS:

PARP inhibitor; bevacizumab; checkpoint inhibitor; chemotherapy; ovarian cancer

Conflict of interest statement

Disclosure and potential conflicts of interest: The authors declare that there is no conflict of interest in preparing this article. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors are available for download at http://www.drugsincontext.com/wp-content/uploads/2018/11/dic.212558-COI.pdf

Publication type

Publication type

Supplemental Content

Full text links

Icon for Just Medical Media Limited Icon for PubMed Central
Loading ...
Support Center